Nanoparticles + radiation: new hope against tough pancreatic cancer?
NCT ID NCT04484909
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new approach for people with pancreatic cancer that cannot be removed right away. Tiny nanoparticles called NBTXR3 are injected directly into the tumor and then activated by radiation therapy. The goal is to find a safe dose and see if this combination can help control the disease. The study involves 24 participants and is led by M.D. Anderson Cancer Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBTXR3 nanoparticles (hafnium oxide) activated by radiation therapy
What this could lead to
If it works, this could lead to a new way to shrink pancreatic tumors and make them easier to remove surgically, potentially improving survival.
What could go wrong
This is a very early Phase 1 trial with only 24 people, so safety and effectiveness are not yet proven. The nanoparticles are injected directly into the pancreas, which carries risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III PANCREATIC CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States